MOG and experimental autoimmune encephalomyelitis: Treatment with mTGF-β1-EXO, even after disease onset, inhibited the development and progression of myelin oligodendrocyte glycoprotein (MOG) peptide-induced experimental autoimmune encephalomyelitis (EAE).